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Abstract
Background: Extrahepatic biliary duct cancers (EBDC) are uncommon malignancies characterized by a poor
prognosis with high rate of loco-regional recurrence. The purpose of the present study is to assess the feasibility
and the potential impact of adjuvant radiotherapy (RT) in a series of patients treated in one institution.
Methods: Twenty three patients with non-metastatic bile duct cancer treated surgically with curative intent (4
gallbladder, 7 ampullary and 12 cholangiocarcinoma) received 3D conformal external beam RT to a median total
dose of 50.4Gy. Concurrent chemotherapy based on 5-FU was delivered to 21 patients (91%). Surgical margins
were negative in 11 patients (48%), narrow in 2 (9%), and microscopically involved in 8 (35%). Eleven patients
(55%) had metastatic nodal involvement. The average follow-up time for all patients was 30 months (ranging from
3-98).
Results: Acute gastrointestinal grade 2 toxicity (RTOG scale) was recorded in 2 patients (9%). Nausea or vomiting
grade 1 and 2 was observed in 8 (35%) and 2 patients (9%) respectively. Only one patient developed a major late
radiation-induced toxicity. The main pattern of recurrence was both loco-regional and distant (liver, peritoneum
and/or lung). No difference was observed in loco-regional control according to the tumor location. The 5-year
actuarial loco-regional control rate was 48.3% (67% and 30% for patients operated on with negative and positive/
narrow/unknown margins respectively, p = 0.04). The 5-year actuarial overall survival was of 35.9% for the entire
group (61.4% in case of negative margins and 16.7% in case of positive/narrow/unknown margins, p = 0.07).
Conclusions: Postoperative RT with 50-60 Gy is feasible with acceptable acute and late toxicities. The potential
benefit observed in our series may support the use of adjuvant RT in patients with locally advanced disease.
Prospective randomized trials are warranted to confirm definitively the role of RT in this tumor location.
Background
Biliary tract cancers are uncommon malignancies. Ade-
nocarcinoma of the gallbladder occurs in 2 cases per
100.000 inhabitants [1], and cholangiocarcinoma and
ampullary cancer in only 1.7 cases per 100.000 inhabi-
tants. The main characteristic of these tumors is their
poor prognosis [2].
To date, the only treatment providing a chance for
cure is surgery. Despite an improvement in surgical
techniques and the use of more aggressive surgical
approaches, only a minority of patients (20-50%) are
suitable for radical procedures [3]. In these resected
patients, improved survival rates have been related to
negative margin status [4]. Patients with initial stages
and negative margins can reach a 5-year survival of
60-70% [5-7]. However, free margins are obtained in no
more than one half of patients [8]. The main patterns of
failure and some clinico-pathological prognostic factors
have been identified in a few retrospective studies,
suggesting that loco-regional recurrence is the most
frequent site of relapse even after aggressive surgical
procedures [9]. Due to this pattern, the addition of
radiotherapy appears as a logical adjuvant treatment
aiming to decrease loco-regional recurrence and
improve survival.
To our knowledge, there is only one phase III rando-
mized trial of adjuvant chemo-radiation involving
patients with resected ampullary cancers [10]. This
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study evaluated a pool of periampullary tumors
(ampulla, duodenum and distal bile duct cancers) and
showed no benefit in adding adjuvant chemo-radiation
to surgery. Thus, given the small number and the retro-
spective nature of published single institution studies,
the impact of adjuvant RT has not been yet clarified.
In our institution, adjuvant RT is proposed to patients
with resected extrahepatic biliary tract cancer presenting
with unfavorable features. The aim of this study is to
assess retrospectively the feasibility and the potential
role of post-operative RT in a series of patients treated
in a single institution.
Methods
Study design: cohort study
38 patients with non-metastatic biliary tract cancer were
treated with radiotherapy in our institution (the Radia-
tion Oncology Department, Geneva University Hospitals,
HUG) between 1998 and 2004. The beginning of this
period corresponds to the start of the routine use of
3D-CRT while the end was chosen to allow a longer fol-
low-up after the treatment. We excluded twelve patients
with unresectable disease and three with intrahepatic
cholangiocarcinoma. The pretreatment patient and dis-
ease characteristics of the remaining 23 patients are
shown in table 1. Stage classification was based on the
pathological findings according to the 5th edition TNM/
American Joint Committee (AJCC) on Cancer staging
system. There were 4 patients with gallbladder cancer, 7
with ampullaly cancer and 12 with cholangiocarcinoma.
According to the recommendations of the HUG’s
Ethical Committee, written informed consent was
obtained from all surviving patients.
Surgical procedures included laparoscopic cholecystect-
omy in 2 patients (9%), partial bile duct resection with or
without hepatectomy in 4 (17%) and 3 (13%) patients
respectively, and pancreatico-duodenectomy with or with-
out partial gastrectomy in 6 (26%) and 7 (30%) patients
respectively. Loco-regional lymph nodes were dissected
with curative intent in 20 patients (87%). The mean
removed nodes was of 11 (range 3-23). All tumors were
adenocarcinoma with a high histological grade in the
majority of cases. Stages III and IVA represented 78% of
patients. Eleven patients (55%) had metastatic nodal invol-
vement. The surgical margins were negative in 11 patients
(47%), narrow in 2 patients (9%), microscopically involved
in 8 (35%) and unknown in 2 (9%).
Target volumes were defined on the basis of clinical
data, preoperative imaging and histopathological find-
ings. All patients received 3-D conformal external beam
RT (EBRT) to the tumor bed and regional lymphatic
drainage according to the tumor location (porta hepatis
and celiac nodes for the entire locations; the perichole-
docal and duodenopancreatic nodes in gallbladder can-
cer; the peripancreatic in cholangiocarcinoma as well
the para-aortic nodes in case of distal tumor location;
and peripancreatic, superior mesenteric artery and para-
aortic nodes in ampullary cancer). RT was delivered by
standard fractionation of 1.8-2 Gy/day, 5 times a week
to a median dose of 45 Gy (range 36-52 Gy), followed
by a boost with reduced fields to a median total dose of
50.4 (rage 45-60 Gy). In only one patient with
Table 1 Tumor and patients characteristics
Gallbladder [n = 4] Extrahepatic cholangiocarcinoma
[n = 12, 3 hilar, 9 distal]
Ampullary [n = 7]
Sex male 1 9 4
female 3 3 3
Age 66 [51-77] 62 [45-77] 63 [54-78]
AJCC stage 5th edition II 2 2 1
III 2 0 6
IVA 0 10 0
Margin status negative 2 4 5
narrow 1 0 1
positive 0 7 1
unknown 1 1 0
Nodal involvement pN0 2 6 1
pN1 2 3 6
pN2 0 1 0
unknown 0 2 0
5-FU based chemotherapy yes 3 12 6
no 1 0 1
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macroscopically positive margins (hepatic parenchyma),
an intraluminal brachytherapy boost was performed (20
Gy in 4 fractions of 5 Gy with Ir-192 sources by percu-
taneous biliary catheterization) after 50.4 Gy of EBRT.
Twenty patients received 5-FU based concomitant che-
motherapy (5FU 500 mg/m2 the first and last 3 days of
RT, 5FU-leucovorin or 5FU-cisplatinum) and one
patient received a daily cisplatinum dose of 6 mg/m2.
All patients had ECOG 1-2 performance status before
treatment, and only two patients did not receive che-
motherapy due to advanced age and comorbidities.
Statistical analysis was performed using the Statistical
Package for the Social Sciences software (SPSS, Chicago,
IL, USA). Survival was calculated according to the
Kaplan-Meier method.
Results
All patients completed the planned EBRT schedule
without interruption. The mean time interval between
surgery and the start of EBRT was 66.5 days. Acute and
late radiation toxicities were assessed according to the
Radiation Therapy Oncology Group (RTOG)/NCI-
CTCAE v3.0 criteria [11]. Acute grade 2 abdominal
pain and diarrhea was recorded in 2 patients (9%). Nau-
sea or vomiting grade 1 and 2 was present in 8 (35%)
and 2 (9%) patients respectively, mostly associated with
concomitant 5-FU-based chemotherapy. No patient pre-
sented acute grade 3 or 4 toxicity. Only one patient
developed a late grade 3 (RTOG) toxicity, consisting in
an anastomotic stenosis which required a partial
gastrectomy.
The median follow-up for all patients was 30 months
(range 3-98). At last follow up 8 patients were alive (7
tumor-free), 14 deceased secondary to cancer failure
and one was lost to follow-up 13 months after treat-
ment. Loco-regional failure was defined as relapse in the
site of the primary tumor and/or the regional lymph
node areas, whereas peritoneal spread was considered as
distant recurrence. We observed 4 in-field failures with
local component, 4 patients with hepatic metastasis, and
distant spread was observed in 8 (peritoneal, pulmonary
and skin). Nine patients developed both loco-regional
and distant spread, which therefore represents the main
pattern of failure in our series.
The 5-year actuarial loco-regional control rate was
48.3%. This figure was 67% and 30% for patients oper-
ated on with negative and positive/narrow/unknown
margins respectively (p = 0.04). The 5-year actuarial
overall survival was 35.9% for the entire group, 61.4%
for patients with negative margins and 16.7% for
patients with positive/narrow/unknown margins (p =
0.07) (figure 1). Patients with stage II (22%) had a med-
ian survival of 52 months compared to 22 months for
patients with stage IV (p = 0.27). Patients with
ampullary location had a non significant higher overall
survival rate (57% vs 24.5%, p = 0.33).
Discussion
Biliary tract cancers are rare diseases. The Geneva
Cancer Registry has reported an incidence of 4.5 cases
per 100,000 inhabitants, associated with a poor 5-year
survival (12% in Switzerland) [2].
Complete surgical resection remains the only potential
curative treatment. However, despite the improvement
in the resectability rates in the last decades, less than
50% of patients would be treated with curative resec-
tions [12,13]. In a recent Japanese cohort study of
patients with biliary tract cancers (ampullary, gallbladder
and cholangiocarcinoma), the 5-year survival rates for
patients with AJCC 2002 stages IA, IB, IIA, IIB, and III
were 85%, 75%, 36%, 20%, and 0%, respectively [14].
In agreement with the WHO classification [15], cho-
langiocarcinoma, gallbladder cancer and ampullary can-
cer have been considered as extrahepatic biliary tract
neoplasms. Some authors advocate classifying this third
location separately since the 5-year survival of ampullary
cancer can reach 80% in early stages [5][7][16].
Although in our series we have observed a better survi-
val of patients with cancer of the ampulla of Vater, this
difference was not statistically significant.
The benefit of adjuvant RT or chemoradiation has not
yet been proved. Due to the rarity of this cancer, it has
been difficult to design prospective randomized clinical
trials. In the other hand, the limitation of the majority
of single institution studies lies in their small sample
sizes, their retrospective nature, and the fact that clin-
ico-pathological features of the irradiated versus
Figure 1 Actuarial overall survival for patients according to the
tumor resection margins.
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observed patients were frequently imbalanced. Concern-
ing ampullary cancer, there is only one prospective trial
namely the phase III EORTC trial published in 1999
[10]. In this study, no clear benefit was associated with
the addition of chemoradiation to surgery for a set of
tumors pertaining to the duodenum, the distal bile duct
and the ampulla of Vater. However one should note
that the study included a mixture of tumor location and
the majority of patients had an early stage disease (60%
of stages T1/T2 and/or node-negative). For gallbladder
cancer, attempts to define the role of adjuvant RT have
led to some analysis of the SEER (Surveillance, Epide-
miology and End Results of the National Cancer Insti-
tute) population databases. Three studies have recently
been published. The first, published by Mojica et al, [17]
analyzed 3187 patients of whom 17% were treated with
adjuvant radiotherapy. It was observed an increase in
median survival with adjuvant treatment (14 versus 8
months, p < 0.001) for the subgroup of patients present-
ing with locally advanced disease and lymph node invol-
vement. The second [18], analyzed a sample of 4180
patients (18% received adjuvant radiotherapy) where
despite the lack of information about the margin status,
surgical technique and/or the use of chemotherapy, the
addition of adjuvant RT was associated with a benefit in
overall survival, particularly for patients with positive
lymph nodes. The third study [19] aimed to define inde-
pendent prognostic factors influencing overall survival.
The use of RT and lymph node involvement were iden-
tified as the main factors with hazard ratios of 0.78 (95%
CI 0.70-0.87, p < 0.01) and 0.65 (95% CI 0.54-0.79, p <
0.01) respectively.
In most of the published single centre studies, patients
with positive lymph nodes and/or positive margins
represents more than 50% of the irradiated patients. The
reported median survival ranges between 13 to 34
months [12][20-22]. We observed a median survival of
49 months for the entire cohort and a better 5-year sur-
vival for patients with negative margins (61.4% vs 16.7%
if positive, narrow and/or unknown).
Few studies have appraised patients’ outcome accord-
ing to loco-regional control, an essential goal when eval-
uating the indication of RT or assessing its efficacy.
Reported rates of relapse range from 50% to 70% [12]
[23-27], and the recurrence rate has been correlated to
the disease stage. Murakami et al. reported a recurrence
rate of 9%, 20%, 60%, 83%, and 100% in stages IA, IB,
IIA, IIB, and III respectively [14]. Generally loco-regio-
nal recurrence occurs in the liver hilum, bilio-enteric
anastomosis, liver resection margins and retroperitoneal
lymph nodes. However, the anatomic definition for
loco-regional relapse is not well defined in the literature.
It is reported by some authors as recurrences in the
tumor bed and/or primary lymph nodes drainage [9],
while others include the recurrences in the peritoneum,
intra-hepatic or at the abdominal wall scar [26]. In
agreement with the first definition, we have considered
peritoneal spread as distant failure, and in our series the
observed loco-regional relapse rate was about 50%,
which is consistent with the reported rates in the
literature.
In our institution, the policy during the trial period
was to administer concurrent 5-FU based chemotherapy.
However, the role of chemotherapy alone or in combi-
nation with radiotherapy remains controversial. 5-FU
has been frequently used in a combined modality
approach because of its potential radiosensitivity [24]
[28,29]. Other chemotherapeutic agents such as gemci-
tabine (alone or combined with fluoropirimidins or oxa-
liplatin) demonstrated a good palliation effect in
advanced tumor stages [30,31]. In the adjuvant setting, a
benefit for patients with gallbladder cancer was shown
in one Japanese randomized trial [32].
Acute toxicity related to adjuvant radiotherapy (with
or without chemotherapy) is usually slight to moderate,
and concerns mainly gastrointestinal symptoms such as
nausea, vomiting or diarrhea. Doses up to 50-54 Gy at
standard fractionation are normally well tolerated and
toxicity rarely exceeds RTOG grades 1-2. Late bleeding
secondary to gastric or duodenal ulcer and necrosis of
the anastomosis requiring surgery are uncommon, with
a reported incidence in the literature of less than 4%
[22][33]. In the present series, only one patient required
a partial gastrectomy for a late toxicity potentially radia-
tion related. Gerhards et al [23] reported the toxicity of
three post-operative approaches: observation, EBRT and
EBRT plus brachytherapy. The toxicity profile was
acceptable with the addition of EBRT, while the addition
of a brachytherapy boost increased significantly local
toxicity. In our study, the patient who developed an ana-
stomotic stricture was treated only with EBRT.
Conclusions
Our study reports the first retrospective data on Swiss
population treated with postoperative RT after radical
surgery in patients with EHBDC. Radiation doses of 50-
60 Gy at standard fractionation in combination with 5-
FU based chemotherapy can be administered with
acceptable acute and late toxicities.
While we observed that patients with positive surgical
margins had a lower survival and loco-regional control,
the low incidence of severe toxicity and the potential
benefit observed in our series may support the indica-
tion for adjuvant RT in patients with locally advanced
disease.
However, given the poor prognosis of this cancer
despite the use of adjuvant therapy, an improvement of
the radiation techniques with dose escalation and/or the
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combination with new chemotherapeutic agents should
be considered in the frame of prospective trials.
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